Nethanel Asher

2.3k total citations
31 papers, 454 citations indexed

About

Nethanel Asher is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Nethanel Asher has authored 31 papers receiving a total of 454 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Nethanel Asher's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (11 papers) and Melanoma and MAPK Pathways (9 papers). Nethanel Asher is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (11 papers) and Melanoma and MAPK Pathways (9 papers). Nethanel Asher collaborates with scholars based in Israel, Netherlands and Switzerland. Nethanel Asher's co-authors include Gal Markel, Guy Ben‐Betzalel, Ronnie Shapira‐Frommer, Jacob Schachter, Tomer Meirson, Yael Steinberg‐Silman, Erez N. Baruch, David Bomze, Ben Boursi and Michal J. Besser and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Neurology.

In The Last Decade

Nethanel Asher

28 papers receiving 448 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nethanel Asher Israel 12 334 117 115 70 36 31 454
Meagan S. Barbee United States 6 232 0.7× 71 0.6× 82 0.7× 91 1.3× 22 0.6× 8 331
Bogdan Fetică Romania 10 151 0.5× 119 1.0× 87 0.8× 50 0.7× 38 1.1× 58 441
Lewis Au United Kingdom 11 267 0.8× 88 0.8× 86 0.7× 81 1.2× 32 0.9× 30 396
Samantha Bowyer Australia 16 489 1.5× 220 1.9× 170 1.5× 92 1.3× 69 1.9× 47 652
Laura Mansi France 12 228 0.7× 85 0.7× 57 0.5× 94 1.3× 34 0.9× 30 373
Amer Sami Canada 12 344 1.0× 184 1.6× 132 1.1× 85 1.2× 102 2.8× 23 551
Fareeda Hosein United States 4 472 1.4× 119 1.0× 190 1.7× 146 2.1× 25 0.7× 8 581
Nancy Nixon Canada 10 233 0.7× 64 0.5× 85 0.7× 69 1.0× 9 0.3× 26 348
Lucia Bonomi Italy 8 256 0.8× 113 1.0× 66 0.6× 220 3.1× 29 0.8× 23 433
Joshua E. Reuss United States 13 370 1.1× 124 1.1× 51 0.4× 257 3.7× 30 0.8× 54 521

Countries citing papers authored by Nethanel Asher

Since Specialization
Citations

This map shows the geographic impact of Nethanel Asher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nethanel Asher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nethanel Asher more than expected).

Fields of papers citing papers by Nethanel Asher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nethanel Asher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nethanel Asher. The network helps show where Nethanel Asher may publish in the future.

Co-authorship network of co-authors of Nethanel Asher

This figure shows the co-authorship network connecting the top 25 collaborators of Nethanel Asher. A scholar is included among the top collaborators of Nethanel Asher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nethanel Asher. Nethanel Asher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Vered, Marilena, Ronnie Shapira‐Frommer, Nethanel Asher, et al.. (2023). Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach. JNCI Journal of the National Cancer Institute. 116(4). 539–546. 11 indexed citations
5.
Markovits, Ettai, Erez N. Baruch, Eldad D. Shulman, et al.. (2023). MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2. Cancer Immunology Research. 11(7). 909–924. 8 indexed citations
6.
Pepys, J., Guy Ben‐Betzalel, Ronnie Shapira‐Frommer, et al.. (2023). Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma. Neurology. 101(24). e2472–e2482. 13 indexed citations
7.
Asher, Nethanel, Aviv Barzilai, Ronnie Shapira‐Frommer, et al.. (2023). The Implications of a Dermatopathologist’s Report on Melanoma Diagnosis and Treatment. Life. 13(9). 1803–1803.
8.
Ben‐Betzalel, Guy, et al.. (2023). Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy. Cancers. 15(11). 3041–3041. 11 indexed citations
9.
Asher, Nethanel, et al.. (2023). Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma. Frontiers in Oncology. 13. 1180988–1180988. 10 indexed citations
10.
Asher, Nethanel, Guy Ben‐Betzalel, Óscar Puig, et al.. (2023). 64 Augmenting low-plex multiplex imaging by leveraging the potential of same-slide H&E analysis. SHILAP Revista de lepidopterología. A74–A74. 1 indexed citations
11.
Asher, Nethanel, et al.. (2023). Exploring the clinical significance of specific immune-related adverse events (irAE) in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy.. Journal of Clinical Oncology. 41(16_suppl). 9566–9566. 1 indexed citations
12.
Asher, Nethanel, et al.. (2022). Oncologic patients’ misconceptions may impede enrollment into clinical trials: a cross-sectional study. BMC Medical Research Methodology. 22(1). 5–5. 6 indexed citations
13.
Furman, Orit, Moran Gadot, Damien Urban, et al.. (2021). Immune checkpoint inhibitors–related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Supportive Care in Cancer. 29(12). 7563–7568. 11 indexed citations
14.
Hermush, Vered, et al.. (2020). Feline cognitive dysfunction as a model for Alzheimer’s disease in the research of CBD as a potential treatment—a narrative review. Journal of Cannabis Research. 2(1). 43–43. 3 indexed citations
15.
Meirson, Tomer, Nethanel Asher, David Bomze, & Gal Markel. (2020). Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation. Cancers. 12(6). 1650–1650. 24 indexed citations
16.
Besser, Michal J., Orit Itzhaki, Guy Ben‐Betzalel, et al.. (2020). Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. Molecular Carcinogenesis. 59(7). 736–744. 22 indexed citations
17.
Ben‐Betzalel, Guy, Yael Steinberg‐Silman, Nethanel Asher, et al.. (2019). Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients. European Journal of Cancer. 108. 61–68. 43 indexed citations
18.
Zippel, Douglas, Gal Markel, Nethanel Asher, et al.. (2019). The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapies. The American Journal of Surgery. 220(2). 349–353. 7 indexed citations
19.
Eshet, Yael, Erez N. Baruch, Ronnie Shapira‐Frommer, et al.. (2018). Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case–Control Study. Cancer Immunology Research. 6(12). 1453–1458. 46 indexed citations
20.
Ben‐Betzalel, Guy, Erez N. Baruch, Ben Boursi, et al.. (2018). Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600–mutant metastatic melanoma. European Journal of Cancer. 101. 229–235. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meagan S. Barbee Breakdown of academic impact, for papers by Bogdan Fetică Breakdown of academic impact, for papers by Lewis Au Breakdown of academic impact, for papers by Samantha Bowyer Breakdown of academic impact, for papers by Laura Mansi Breakdown of academic impact, for papers by Amer Sami Breakdown of academic impact, for papers by Fareeda Hosein Breakdown of academic impact, for papers by Nancy Nixon Breakdown of academic impact, for papers by Lucia Bonomi Breakdown of academic impact, for papers by Joshua E. Reuss
Rankless by CCL
2026